Skip to main content
Federal & State Lawfederalstatelaw.com
Home/Federal/Bills (Live)
HOUSE 3433118th CongressReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Give Kids a Chance Act of 2024

Last Action
9/24/2024

Actions

  • 2024-09-24Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  • 2024-09-23Motion to reconsider laid on the table Agreed to without objection.
  • 2024-09-23On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5582-5585)
  • 2024-09-23Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5582-5585)
  • 2024-09-23DEBATE - The House proceeded with forty minutes of debate on H.R. 3433.
  • 2024-09-23Considered under suspension of the rules. (consideration: CR H5582-5587)
  • 2024-09-23Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
  • 2024-09-20Placed on the Union Calendar, Calendar No. 594.
  • 2024-09-20Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-700.
  • 2024-09-20Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-700.
  • 2024-09-18Ordered to be Reported (Amended) by the Yeas and Nays: 43 - 0.
  • 2024-09-18Committee Consideration and Mark-up Session Held
  • 2024-05-16Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 16 - 11.
  • 2024-05-16Subcommittee Consideration and Mark-up Session Held
  • 2023-05-19Referred to the Subcommittee on Health.

Showing 15 of 18 actions. Full history on Congress.gov.

CRS Summary

As of 2023-05-17 (00)

Give Kids a Chance Act of 2023

This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer.

Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations so as to authorize investigations of new drugs that are used in combination with active ingredients that have already been approved and that (1) have been determined to be the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.

The Food and Drug Administration must issue guidance and report on the bill's implementation. The Government Accountability Office must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.

Cosponsors (20)

  • ANNA ESHOO (D-CA)
  • Mike Kelly (R-PA)
  • Young Kim (R-CA)
  • CHRISTOPHER SMITH (R-NJ)
  • Kim Schrier (D-WA)
  • Don Bacon (R-NE)
  • James Moylan (R-GU)
  • Vern Buchanan (R-FL)
  • Brian Fitzpatrick (R-PA)
  • Bill Huizenga (R-MI)
  • Glenn Grothman (R-WI)
  • Bill Johnson (R-OH)
  • Dean Phillips (D-MN)
  • Ann Kuster (D-NH)
  • Joe Wilson (R-SC)
  • Maria Salazar (R-FL)
  • Joe Neguse (D-CO)
  • Nick LaLota (R-NY)
  • David Valadao (R-CA)
  • Kevin Mullin (D-CA)

Subjects

  • Cancer
  • Child health
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Drug therapy
  • Government studies and investigations
  • Medical research
  • Prescription drugs
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.